These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Goals and targets for personalized therapy for HCC. Couri T; Pillai A Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478 [TBL] [Abstract][Full Text] [Related]
5. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Poon RT; Fan ST; Tsang FH; Wong J Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602 [TBL] [Abstract][Full Text] [Related]
6. Liver-directed therapy for hepatocellular carcinoma. O'Leary C; Mahler M; Soulen MC Chin Clin Oncol; 2021 Feb; 10(1):8. PubMed ID: 32527111 [TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma: locoregional and targeted therapies. Wong R; Frenette C; Gish R Gastroenterol Clin North Am; 2011 Sep; 40(3):599-610. PubMed ID: 21893276 [TBL] [Abstract][Full Text] [Related]
9. Assessment of the treatment response of HCC. Kim KW; Lee JM; Choi BI Abdom Imaging; 2011 Jun; 36(3):300-14. PubMed ID: 21279353 [TBL] [Abstract][Full Text] [Related]
10. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Brown ZJ; Hewitt DB; Pawlik TM Expert Opin Investig Drugs; 2022 Apr; 31(4):379-391. PubMed ID: 34788184 [TBL] [Abstract][Full Text] [Related]
11. Current locoregional therapies and treatment strategies in hepatocellular carcinoma. Cardarelli-Leite L; Hadjivassiliou A; Klass D; Chung J; Ho SGF; Lim HJ; Kim PTW; Mujoomdar A; Liu DM Curr Oncol; 2020 Nov; 27(Suppl 3):S144-S151. PubMed ID: 33343208 [TBL] [Abstract][Full Text] [Related]
12. The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. Peng Z; Wu X; Li J; Pang H; Zhang Y; Lin M; Wang Z; Xiao H; Li B; Chen M; Feng S; Kuang M; Chen S Int J Hyperthermia; 2022; 39(1):688-696. PubMed ID: 35469522 [TBL] [Abstract][Full Text] [Related]
13. Transarterial radioembolization for liver tumors as neoadjuvant therapy: three case reports. Carvalho VO; Galastri FL; Affonso BB; Falsarella PM; Valle LGM; Ferraz-Neto BH; Rezende MB; Motta-Leal-Filho JMD; Garcia RG; Nasser F Einstein (Sao Paulo); 2020; 18():eRC4990. PubMed ID: 32130329 [TBL] [Abstract][Full Text] [Related]
14. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460 [TBL] [Abstract][Full Text] [Related]
15. The current role of neoadjuvant/adjuvant/chemoprevention therapy in partial hepatectomy for hepatocellular carcinoma: a systematic review. Lau WY; Lai EC; Lau SH Hepatobiliary Pancreat Dis Int; 2009 Apr; 8(2):124-33. PubMed ID: 19357024 [TBL] [Abstract][Full Text] [Related]
16. Emerging Trends in the Treatment of Advanced Hepatocellular Carcinoma: A Radiological Perspective. Kim GH; Kim JH; Kim PH; Chu HH; Gwon DI; Ko HK Korean J Radiol; 2021 Nov; 22(11):1822-1833. PubMed ID: 34431250 [TBL] [Abstract][Full Text] [Related]
18. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Hui RW; Mak LY; Cheung TT; Lee VH; Seto WK; Yuen MF Clin Mol Hepatol; 2023 Apr; 29(2):217-229. PubMed ID: 36577426 [TBL] [Abstract][Full Text] [Related]
19. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial. Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA Trials; 2012 Aug; 13():144. PubMed ID: 22913492 [TBL] [Abstract][Full Text] [Related]